Concomitant Versus Staged Percutaneous Cervicocerebral Artery Revascularization with Coronary Artery Bypass Grafting [0.03%]
经皮颈动脉和脑动脉联合冠状动脉旁路移植血管成形术与分期手术的比较研究
Jinwei Zhang,Liaoming He,Chenzhen Xu et al.
Jinwei Zhang et al.
Introduction: The optimal strategy and timing for percutaneous cervicocerebral artery revascularization (PCAR) combined with coronary artery bypass grafting (CABG) remain uncertain in patients with severe carotid or verte...
Advanced Cardiac Imaging Techniques for Detection of Myocardial Ischemia in Children with Coronary Artery Abnormalities [0.03%]
儿童冠状动脉畸形心肌缺血的先进心脏影像技术检测手段
Justin B Jin,Jason L Williams,Siew May Wang et al.
Justin B Jin et al.
Introduction: Coronary artery disease in children arises from a diverse group of non-atherosclerotic conditions that may result in myocardial ischemia, ventricular dysfunction, and sudden cardiac death. Important etiologi...
Real-World Analysis of the Association Between Systemic Inflammation, Cardiovascular Events, and Economic Burden Among Patients with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease [0.03%]
动脉粥样硬化性心血管病合并慢性肾脏疾病患者全身炎症与心血管事件及经济负担相关性的真实世界研究
Chi Nguyen,Radha Ryali,Jeffrey R Skaar et al.
Chi Nguyen et al.
Introduction: Patients with atherosclerotic cardiovascular disease (ASCVD) and systemic inflammation (SI) or chronic kidney disease (CKD) have poorer outcomes than those without SI or CKD. This study evaluated the impact ...
Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice [0.03%]
ACORAMIDIS真实世界研究（ACO-REAL）的设计与 rationale
Marianna Fontana,Francesco Cappelli,Julian D Gillmore et al.
Marianna Fontana et al.
Introduction: Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study, ATTRibute-C...
Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials: Time for an Update? [0.03%]
ATTR淀粉样变性临床试验中定义心力衰竭终点的现状与展望？
Diona Gjermeni,Kevin M Alexander,James L Januzzi et al.
Diona Gjermeni et al.
This viewpoint highlights the critical need for a standardized definition of heart failure (HF) endpoints in clinical trials specific to transthyretin cardiac amyloidosis (ATTR-CA). Current endpoint definitions vary significantly across sta...
The 'Chloride Theory' for Heart Failure Pathophysiology: An Updated Narrative Review 2025 [0.03%]
心力衰竭病理生理学的“氯离子理论”：2025年更新叙述性综述
Hajime Kataoka
Hajime Kataoka
Most studies of heart failure (HF) syndromes have focused on fluid regulation, particularly the balance of sodium and water. Approximately 10 years ago, in 2017, the "chloride theory" was proposed as a unifying hypothesis, suggesting that c...
Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up [0.03%]
德琅地司特莫氧帕伏塞临床试验中长达五年随访的杜氏肌营养不良症的心脏安全性结果
Aravindhan Veerapandiyan,John Bourke,Jonathan H Soslow et al.
Aravindhan Veerapandiyan et al.
Introduction: In patients with Duchenne muscular dystrophy (DMD), the gene transfer therapy delandistrogene moxeparvovec delivers a functional form of dystrophin, which has been shown to stabilize or slow disease progress...
A Patient and Physician Perspective of Chronic Coronary Syndrome and Persistent Stable Angina in Brazil [0.03%]
从患者和医生的视角看巴西的慢性冠状动脉综合征和持续型稳定型心绞痛
Antônio Figueiredo Araújo,Aparecida de Fátima Machado Tavares,Luís Henrique Wolff Gowdak
Antônio Figueiredo Araújo
Obstructions in the coronary arteries, arterial vasospasm, and microcirculation dysfunction may cause chronic coronary syndrome (CCS). Angina is a cardinal symptom of CCS and the journey of patients with angina is often filled with challeng...
Utilization Patterns and Barriers to Sodium-Glucose Cotransporter-2 Inhibitor Prescription in Patients with Heart Failure: Real-World Evidence from Saudi Arabia [0.03%]
沙特阿拉伯心力衰竭患者钠-葡萄糖共转运蛋白2抑制剂处方使用情况及障碍：真实世界证据
Lama Alfehaid,Omar Alkhezi,Riyadh Alrayes et al.
Lama Alfehaid et al.
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended as foundational therapy for patients with heart failure (HF) across all ejection fractions; however, real-world adoption remains inconsisten...
Repurposing Empagliflozin for Duchenne Muscular Dystrophy-Associated Cardiomyopathy: Protocol for a Pharmacokinetics, Safety and Proof-of-Concept Trial in Children [0.03%]
恩格列净治疗杜氏肌营养不良症相关的心肌病：儿童药代动力学、安全性和概念验证试验方案
Sebastiano A G Lava,Craig Laurence,Janet Mallory et al.
Sebastiano A G Lava et al.
Introduction: Duchenne muscular dystrophy (DMD) is a life-limiting disease characterized by progressive muscle wasting of skeletal and cardiac myocytes. Nowadays, heart failure is the principal cause of death. Current tre...